ACOG
What one share of Alpha Cognition holds
Biological Products, (No Diagnostic Substances)
We focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation.
Alpha Cognition’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.74 |
|---|---|
| Profit | −$1.05 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.51 |
| Cash and investments | $1.90 |
| Book value | $2.43 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$3.84 | — | −$2.45 | — | −$0.99 |
| 2024 | — | −$2.04 | $0.00 | −$1.07 | — | — |
| 2025 | $0.58 | −$1.18 | $0.02 | −$1.17 | — | $2.88 |